We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug News
    • Trending
    • Commercial Operations
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Drug Daily Bulletin
    • Drug Industry Daily
  • Device News
    • Trending
    • Commercial Operations
    • Inspections and Audits
    • Postmarket Safety
    • Quality
    • Regulatory Affairs
    • Research and Development
    • Submissions and Approvals
    • FDAnews Device Daily Bulletin
    • FDAnews Device Daily Bulletin Premium
  • Books
    • FDAnews Books Library
    • Drug Books
    • Device Books
  • Training/Events
    • Webinar Training Pass
    • Events
  • Resources
    • Form 483s Database
    • FDA Approved Drugs
    • eCFR and Guidances
    • White Papers
  • CenterWatch
  • About Us
    • The Company
    • Contact Us
  • Advertising
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Boston Scientific’s S-ICD Wins Favorable Coding and Payment Designations for 2015

Boston Scientific’s S-ICD Wins Favorable Coding and Payment Designations for 2015

November 14, 2014

Boston Scientific said Thursday that its under-the-skin cardiac defibrillator, the S-ICD System, has received designated Current Procedural Terminology Category I codes, effective Jan. 1.

The coding system, developed and administered by the American Medical Association, gives U.S. doctors and hospitals a uniform process for coding medical services, and CPTI Category I includes widely performed procedures.

Also starting Jan. 1, the Medicare hospital outpatient payment rate for the S-ICD will increase by 23 percent, Boston Scientific noted. And private payer Aetna has broadened its coverage for the S-ICD to all patients who meet the criteria for an ICD and are not contraindicated, joining other health plans that have done the same, the company said.

Together, the new coding designation and coverage changes should increase patient access to the S-ICD, said Michael Gold, director of cardiology at the University of South Carolina.

According to devicemaker, the S-ICD is the world’s least invasive implantable defibrillator, offering protection for patients at risk of sudden cardiac arrest without actually touching the heart and blood vessels. — Kellen Owings

Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.

Devices Regulatory Affairs

Upcoming Events

  • 04Apr

    Optimizing Quality Control Operations with Unified Quality

  • 12Apr

    The Participant Playbook Webinar Series, Part 3 — Rethinking the Development of Participant-Centric Clinical Trial Technology

  • 20Apr

    Medical Device Enforcement: Latest Developments from the FDA, DOJ and FTC

  • 25Apr

    Effective Root Cause Analysis and CAPA Investigations for Drugs, Devices and Clinical Trials

  • 26Apr

    FDA’s New Laws and Regulations: What Drug and Biologics Manufacturers Need to Know

  • 26Apr

    Building the Foundation for QMS AI

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • FDA Final Order Requires PMA for Spinal Spheres

  • FDA and Lupus Research Alliance Form Drug Development Consortium

  • GSK and Scynexis Ink Antifungal Licensing Deal Drug

  • FDA Clears Bot Image’s AI Software for Prostate Cancer Screening

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell or Share My Data
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing